Compare · ABT vs APLM
ABT vs APLM
Side-by-side comparison of Abbott Laboratories (ABT) and Apollomics Inc. (APLM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and APLM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $154.95B, about 4494.2x APLM ($34.5M).
- Over the past year, ABT is down 32.3% and APLM is up 167.0% - APLM leads by 199.4 points.
- ABT has been more active in the news (10 items in the past 4 weeks vs 4 for APLM).
- ABT has more recent analyst coverage (25 ratings vs 0 for APLM).
- Company
- Abbott Laboratories
- Apollomics Inc.
- Price
- $88.95-3.44%
- $15.22-10.21%
- Market cap
- $154.95B
- $34.5M
- 1M return
- -0.77%
- +10.37%
- 1Y return
- -32.34%
- +167.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
- Abbott hosts conference call for second-quarter earnings
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
Latest APLM
- SEC Form 6-K filed by Apollomics Inc.
- Apollomics Regains Full Compliance with Nasdaq Listing Requirements
- SEC Form 6-K filed by Apollomics Inc.
- Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
- Chief Financial Officer Lin Peter Kuan-How converted options into 10,000 units of CLASS A ORDINARY SHARES and covered exercise/tax liability with 3,588 units of CLASS A ORDINARY SHARES, increasing direct ownership by 40% to 22,312 units (SEC Form 4)
- Chief Executive Officer Chen Hung-Wen converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 3% to 148,334 units (SEC Form 4)
- Director Chu Yi-An converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Director Chen Hong-Jung converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 16% to 3,620 units (SEC Form 4)
- Director Tsai Hsien-Shu converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Chief Operating Officer Chen Yi-Kuei converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 15,000 units (SEC Form 4)